Aileron Therapeutics, Inc.
ALRN US
ALRN USAileron Therapeutics, Inc.
United States Composite3.08
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. James Brian Windsor Ph.D.
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12407 N. Mopac Expy. Austin TX United States 78758
- IPO Date
- Jun 29, 2017
- Website
- www.aileronrx.com
- Business
- Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Company News
Aileron Therapeutics to be Included in the Russell Microcap® Index
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics announces positive data from its early stage pulmonary fibrosis treatment trial
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million